메뉴 건너뛰기




Volumn 24, Issue 3, 2013, Pages 169-178

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

Author keywords

Corticosteroids; Etanercept; Psoriasis; Safety; Treatment efficacy; Vitamin D analogue

Indexed keywords

CORTICOSTEROID; ETANERCEPT; VITAMIN D;

EID: 84877060491     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.658015     Document Type: Article
Times cited : (58)

References (15)
  • 1
    • 68949149916 scopus 로고    scopus 로고
    • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
    • Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61: 451-485.
    • (2009) J Am Acad Dermatol. , vol.61 , pp. 451-485
    • Menter, A.1    Korman, N.J.2    Elmets, C.A.3    Feldman, S.R.4    Gelfand, J.M.5    Gordon, K.B.6
  • 2
    • 0037331055 scopus 로고    scopus 로고
    • The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial
    • De Jong EM, Mork NJ, Seijger MM, De La Brassine M, Lauharanta J, Jansen CT, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial. Br J Dermatol. 2003;148:318-325.
    • (2003) Br J Dermatol. , vol.148 , pp. 318-325
    • De Jong, E.M.1    Mork, N.J.2    Seijger, M.M.3    De La Brassine, M.4    Lauharanta, J.5    Jansen, C.T.6
  • 3
    • 0031883423 scopus 로고    scopus 로고
    • Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris
    • Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 1998;10:143-146.
    • (1998) J Eur Acad Dermatol Venereol. , vol.10 , pp. 143-146
    • Kokelj, F.1    Torsello, P.2    Plozzer, C.3
  • 9
    • 21644481166 scopus 로고    scopus 로고
    • A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
    • Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths C, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
    • (2005) Br J Dermatol. , vol.152 , pp. 1304-1312
    • Papp, K.A.1    Tyring, S.2    Lahfa, M.3    Prinz, J.4    Griffiths, C.5    Nakanishi, A.M.6
  • 10
    • 54249097066 scopus 로고    scopus 로고
    • Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension
    • van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension. Br J Dermatol. 2008;159:1177-1185.
    • (2008) Br J Dermatol. , vol.159 , pp. 1177-1185
    • Van De Kerkhof, P.C.1    Segaert, S.2    Lahfa, M.3    Luger, T.A.4    Karolyi, Z.5    Kaszuba, A.6
  • 11
    • 0032717253 scopus 로고    scopus 로고
    • Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The cavide research group
    • Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The cavide research group. Br J Dermatol. 1999; 141:698-702.
    • (1999) Br J Dermatol. , vol.141 , pp. 698-702
    • Badia, X.1    Mascaro, J.M.2    Lozano, R.3
  • 12
    • 18944404879 scopus 로고    scopus 로고
    • Current severe psoriasis and the rule of tens
    • Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-867.
    • (2005) Br J Dermatol. , vol.152 , pp. 861-867
    • Finlay, A.Y.1
  • 13
    • 33750492269 scopus 로고    scopus 로고
    • The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study
    • Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
    • (2006) Health Qual Life Outcomes. , vol.4 , pp. 71
    • Shikiar, R.1    Willian, M.K.2    Okun, M.M.3    Thompson, C.S.4    Revicki, D.A.5
  • 14
    • 76149102966 scopus 로고    scopus 로고
    • Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
    • Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
    • (2010) BMJ , vol.340
    • Sterry, W.1    Ortonne, J.P.2    Kirkham, B.3    Brocq, O.4    Robertson, D.5    Pedersen, R.D.6
  • 15
    • 70449492883 scopus 로고    scopus 로고
    • Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The crystel study
    • Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson CD, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23: 1374-1382.
    • (2009) J Eur Acad Dermatol Venereol. , vol.23 , pp. 1374-1382
    • Dauden, E.1    Griffiths, C.E.2    Ortonne, J.P.3    Kragballe, K.4    Molta, C.T.5    Robertson, C.D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.